Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trial; ACH-5548, a factor D inhibitor; and other factor D inhibitors. It has license agreements with GCA Therapeutics, Ltd and Ora, Inc., as well as a collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize drug candidates for the treatment of chronic hepatitis C virus. The company was founded in 1998 and is headquartered in New Haven, Connecticut.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ACHN
Previous Symbol
CUSIP00448Q20
Phone203-624-7000
Debt
Debt-to-Equity RatioN/A
Current Ratio33.23
Quick Ratio33.23
Price-To-Earnings
Trailing P/E Ratio-5.15
Forward P/E Ratio-6.13
P/E GrowthN/A
Sales & Book Value
Annual Sales$15 million
Price / Sales29.48
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.35 per share
Price / Book1.36
Profitability
EPS (Most Recent Fiscal Year)($0.62)
Net Income$-85,230,000.00
Net MarginsN/A
Return on Equity-25.48%
Return on Assets-24.70%
Miscellaneous
Employees88
Outstanding Shares138,620,000
Market Cap$431.10 million
OptionableOptionable
Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions
What is Achillion Pharmaceuticals' stock symbol?
Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."
How were Achillion Pharmaceuticals' earnings last quarter?
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.02. View Achillion Pharmaceuticals' Earnings History.
When is Achillion Pharmaceuticals' next earnings date?
What price target have analysts set for ACHN?
2 brokerages have issued twelve-month price objectives for Achillion Pharmaceuticals' shares. Their predictions range from $3.50 to $5.00. On average, they anticipate Achillion Pharmaceuticals' stock price to reach $4.25 in the next year. This suggests a possible upside of 33.2% from the stock's current price. View Analyst Price Targets for Achillion Pharmaceuticals.
What is the consensus analysts' recommendation for Achillion Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achillion Pharmaceuticals.
Has Achillion Pharmaceuticals been receiving favorable news coverage?
News stories about ACHN stock have trended extremely positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Achillion Pharmaceuticals earned a coverage optimism score of 5.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Are investors shorting Achillion Pharmaceuticals?
Achillion Pharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totalling 5,561,629 shares, a decrease of 23.9% from the October 31st total of 7,307,473 shares. Based on an average daily trading volume, of 1,511,653 shares, the short-interest ratio is presently 3.7 days. Currently, 4.1% of the shares of the stock are short sold. View Achillion Pharmaceuticals' Current Options Chain.
Who are some of Achillion Pharmaceuticals' key competitors?
Some companies that are related to Achillion Pharmaceuticals include Reata Pharmaceuticals (RETA), PTC Therapeutics (PTCT), Biohaven Pharmaceutical (BHVN), The Medicines (MDCO), Cambrex (CBM), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Vanda Pharmaceuticals (VNDA), Enanta Pharmaceuticals (ENTA), Wave Life Sciences (WVE), Esperion Therapeutics (ESPR), Portola Pharmaceuticals (PTLA), Aimmune Therapeutics (AIMT), Nabriva Therapeutics (NBRV) and Phibro Animal Health (PAHC).
Who are Achillion Pharmaceuticals' key executives?
Achillion Pharmaceuticals' management team includes the folowing people:
- Mr. Joseph Truitt, Pres, CEO & Director (Age 53)
- Ms. Mary Kay Fenton, Exec. VP, CFO & Treasurer (Age 54)
- Ms. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 63)
- Mr. Paul Firuta, Exec. VP & COO (Age 52)
- Mr. Brian R. DiDonato, VP of Investor Relations & Corp. Communications (Age 51)
Who are Achillion Pharmaceuticals' major shareholders?
Achillion Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.60%), Vanguard Group Inc. (8.45%), Dimensional Fund Advisors LP (5.18%), Point72 Asset Management L.P. (1.30%), Teachers Advisors LLC (1.27%) and Baker BROS. Advisors LP (1.18%). Company insiders that own Achillion Pharmaceuticals stock include & Johnson Johnson and Jason S Fisherman. View Institutional Ownership Trends for Achillion Pharmaceuticals.
Which major investors are selling Achillion Pharmaceuticals stock?
ACHN stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Renaissance Technologies LLC, TIAA CREF Investment Management LLC, Baker BROS. Advisors LP, Panagora Asset Management Inc., Tekla Capital Management LLC, Virtus ETF Advisers LLC and Credit Suisse AG. View Insider Buying and Selling for Achillion Pharmaceuticals.
Which major investors are buying Achillion Pharmaceuticals stock?
ACHN stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Nexthera Capital LP, Assenagon Asset Management S.A., Marshall Wace North America L.P., Vanguard Group Inc., Opus Point Partners Management LLC, Dimensional Fund Advisors LP and Opaleye Management Inc.. View Insider Buying and Selling for Achillion Pharmaceuticals.
How do I buy shares of Achillion Pharmaceuticals?
Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Achillion Pharmaceuticals' stock price today?
One share of ACHN stock can currently be purchased for approximately $3.19.
How big of a company is Achillion Pharmaceuticals?
Achillion Pharmaceuticals has a market capitalization of $431.10 million and generates $15 million in revenue each year. The biopharmaceutical company earns $-85,230,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Achillion Pharmaceuticals employs 88 workers across the globe.
What is Achillion Pharmaceuticals' official website?
How can I contact Achillion Pharmaceuticals?
Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.
MarketBeat Community Rating for Achillion Pharmaceuticals (NASDAQ ACHN)
MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACHN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHN will underperform the S&P 500 over the long term. You may vote once every thirty days.
